Press releases, media coverage, and where to find the Celltaxis team at upcoming scientific and industry meetings.
Clinical data published in Scientific Reports describe improvements in limb volume, skin thickness, tissue architecture, and quality of life during a 12-month, open-label study of once-daily oral acebilustat in patients with chronic lymphedema, supporting further development of Celltaxis's approach to lymphatic repair.
Read the releaseSeptember 22, 2026
Celltaxis CEO and co-founder Eileen Heffernan joins host Karen Jagoda on the Empowered Patient Podcast to discuss lymphedema, the most common lymphatic disorder, and why Celltaxis's approach of immune modulation and lymphatic vessel repair could shift treatment from symptom management to disease modification.
Listen to the episodeAugust 10, 2026
Tiberend's Bench2Bedside profiles Celltaxis's oral small-molecule approach to lymphedema and lipedema, which targets the inflammatory biology that suppresses lymphatic repair rather than managing symptoms, and looks ahead to the company's next-generation candidate.
Read on Bench2Bedside
June 15, 2026
Celltaxis promoted co-founder and former Chief Business Officer Eileen Heffernan to CEO to lead strategic growth, clinical advancement, and partnerships in lymphatic disease therapeutics.
Read the releaseOctober 28–31, 2026 · Rome, Italy
Stanford University investigators will present clinical data on acebilustat at the ILF World Congress, which brings together clinicians, researchers, and patient advocates from around the world to advance the care of lymphoedema and related conditions.
Congress detailsNovember 17, 2026 · New York, NY
Celltaxis is a Presenting Sponsor of LE&RN's Pathways to Progress Gala, an evening honoring leaders in lymphatic medicine and philanthropy while raising funds for lymphatic disease research, patient care, and awareness. Celltaxis medical advisor Stanley G. Rockson, MD, a co-founder of LE&RN, serves as Honorary Gala Chair.
Gala detailsJanuary 11–14, 2027 · San Francisco, CA
The Celltaxis team will be in San Francisco for the industry's largest healthcare investment symposium, connecting with investors, partners, and fellow innovators across the life sciences.
Conference detailsJanuary 11–13, 2027 · San Francisco, CA
Held alongside the J.P. Morgan Healthcare Conference, Biotech Showcase brings emerging life science companies together with more than 1,200 investors for presentations and partnering meetings. Connect with the Celltaxis team during the conference.
Event detailsFor press materials, interview requests, or partnership discussions, reach out to the Celltaxis team directly.
Get in touch